XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
A number of studies on the relationship between xeroderma pigmentosum group G (XPG) polymorphisms and clinical outcomes in non-small cell cancer (NSCLC) have led to inconclusive results. This meta-analysis evaluates the predictive value of XPG polymorphisms on the treatment response rate and overall survival of patients with NSCLC.



To measure the correlative strength of the relationship between XPG polymorphisms and outcomes of patients with NSCLC, we searched electronic databases, including PubMed and China National Knowledge Infrastructure, to retrieve studies up to August 2016. We also employed pooled odds ratios (ORs) and hazard ratios (HRs) corresponding to 95% confidence intervals (95% CIs).



Twelve studies involving 2877 patients with NSCLC were included: 8 studies involving 1473 patients examined the correlation between XPG polymorphisms and tumor response rate and 7 studies involving 2329 patients reported on the correlation of XPG polymorphisms with overall survival. None of the XPG His1104Asp(C>G)/His46His(C>T) polymorphisms exhibited a correlation with treatment response rate or overall survival. However, in a further stratified analysis by ethnicity, carriers of the 1104G allele were associated with good response among Asians in the homozygote model (GG vs. CC: OR = 1.57, 95% CI: 1.05-2.34, P = 0.027). Meanwhile, further stratified by ethnicity, His46His polymorphism was not associated with RR and OS in any genetic models.



No strong evidence was found to support the use of XPG polymorphisms as tumor response and prognostic factors of patients with NSCLC receiving a platinum-based treatment regimen, which is attributed to marginal association. Studies with large-scale and multiple ethnicities need to be conducted to verify the conclusion.
Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Tianxin
T
Xiang
Department of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiuhua
X
Kang
Shenzhen Peking University and Hong Kong University of Science and Technology Medical Center, FuTian District, Shenzhen, China.
Zhenghua
Z
Gong
Department of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Wei
W
Bai
Department of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Chuanhui
C
Chen
Department of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China. ndzhangwei2016@126.com.
Wei
W
Zhang
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000032:analysis / Q000235:genetics*; D004720:Endonucleases / Q000032:analysis / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009687:Nuclear Proteins / Q000032:analysis / Q000235:genetics*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis; D014157:Transcription Factors / Q000032:analysis / Q000235:genetics*; D016896:Treatment Outcome; D000099250:DNA Excision Repair Protein ERCC-5
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D004720:Endonucleases; D009687:Nuclear Proteins; D009944:Organoplatinum Compounds; D014157:Transcription Factors; D000099250:DNA Excision Repair Protein ERCC-5
Meta-analysis; Non-small cell lung cancer; Platinum; Polymorphism; XPG